New 'Reaxys' Solution Improves Workflow Quality...

FRANKFURT, Germany, January 26 /PRNewswire/ --

    - Elsevier's New Web-Based Solution Combines Content From the Trusted
CrossFire Databases in a Highly Intuitive and Easy to use Interface With New
Features and Functionality



    Elsevier, the leading publisher of scientific, medical and
technical products and services, today introduced Reaxys, a new workflow
solution for synthetic chemists. Reaxys is based on data from Elsevier's
industry leading chemistry databases (CrossFire Beilstein, CrossFire Gmelin
and Patent Chemistry Database) now merged together to provide harmonized
content, additional functionalities and a redesigned interface to help
improve R&D efficiency. Reaxys also contains new unique features including a
synthesis planner and advanced results handling to help scientists gather
relevant information more efficiently.



    "Scientists, both in academia and industry, are under increasing 
pressure to deliver more and better results in a shorter time and
make research decisions faster," said Mark van Mierle, managing director for
Elsevier Information Systems. "Reaxys now gives them a tool to quickly create
an overview of the of synthesis design options available for their work,
research and quickly identify and select the most appropriate. By integrating
chemical reaction and substance data from trusted sources with a synthesis
design process, customers can accelerate early phase discovery."


    
    Features include:

    - Workflow and decision making support for synthesis design and
      planning, e.g. by comparing alternative synthesis routes and selecting
      the most relevant paths;
    - Quick access to key data by displaying results in a unique
      tabulated overview of the most important information;
    - Convenient and flexible output of data in most common formats.





    Reaxys has been developed with input and advice from development partners
from corporate and academic research institutions around the world. In 
addition, the web interface has been designed by experts in
human-computer interaction. The look and feel has been streamlined to make
searching easier and provide a clear visualization of the results.



    The result is a solution that goes beyond retrieving data.
Search results reflect how chemists think and work, helping their workflow
move seamlessly from initial search, recognition of possible starting
materials and their properties and through planning a strategy for the
synthesis of a new compound to proposing a detailed synthetic route. Most
compounds in Reaxys can be identified by their CAS Registry Numbers(R).



Migrating from Crossfire to Reaxys

    Reaxys is available today and existing CrossFire customers may
use Reaxys in parallel for an interim period. Elsevier offers full training
and helpdesk support for new customers as well as guidance for the migration
from CrossFire to the new platform. For the time being all CrossFire products
as well as the Commander interface will be fully supported.



    Select customers have been evaluating Reaxys throughout its
development and have provided positive feedback. Elsevier will continue to
engage with the chemistry community in future product development. For more
information, visit http://www.info.reaxys.com.



About Elsevier

    Elsevier is a world-leading publisher of scientific, technical
and medical information products and services. Working in partnership with
the global science and health communities, Elsevier's 7,000 employees in over
70 offices worldwide publish more than 2,000 journals and 1,900 new books per
year, in addition to offering a suite of innovative electronic products, such
as ScienceDirect (http://www.sciencedirect.com/), MD Consult 
(http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),
bibliographic databases, and online reference works.



    Elsevier (http://www.elsevier.com/) is a global business
headquartered in Amsterdam, The Netherlands and has offices worldwide.
Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a
world-leading publisher and information provider. Operating in the science
and medical, legal, education and business-to-business sectors, Reed Elsevier
provides high-quality and flexible information solutions to users, with
increasing emphasis on the Internet as a means of delivery. Reed Elsevier's
ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK
and ENL (New York Stock Exchange).



    Reaxys(TM) and CrossFire Beilstein are owned and protected by Elsevier 
Properties SA and used under license.



    More about the addition of CAS Registry Numbers(R) can be
found in a recent agreement between CAS (Chemical Abstract Service) and
Elsevier: http://www.info.reaxys.com/press_room.



    
    Tom Reller (For U.S.)
    Director, Corp. Relations
    [phone]
    [e-mail]

    Emma Potter (Europe/Asia)
    Kaizo Public Relations
    [phone]
    [e-mail]